2026-02-26 14:00Financial Data and Key Metrics Changes - In Q4 2025, total revenue increased by 17% year-over-year to $127.6 million, with full-year revenues growing by 15% to $460.2 million [20][21] - Loss from operations improved by 19% for the full year to $229.4 million, and improved by 25% when adjusted for non-cash expenses [21] - The company ended the quarter with a strong cash position of $790 million [21] Business Line Data and Key Metrics Changes - The China business provided stability, with full-year revenue growth of 15% year-over-year [6] - XACDURO and NUZYRA contributed significantly to revenue growth, with XACDURO showing strong patient demand despite supply constraints [20] - VYVGART's revenue was stable, but Q4 reflected channel dynamics related to NRDL renewal and hospital purchasing patterns [17] Market Data and Key Metrics Changes - The company anticipates good growth opportunities for VYVGART and ZEJULA in 2026, despite facing a generic market for Lynparza [24] - The total addressable market for Zoci in small cell lung cancer and neuroendocrine carcinomas is estimated to exceed $9 billion [11] Company Strategy and Development Direction - The company is focused on execution and preparation for 2026, with several pipeline catalysts expected [6] - Business development remains a key lever, with targeted collaborations to explore novel combination strategies in oncology [17] - The company aims to build a lasting difference for patients while creating substantial value for shareholders [7] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of maintaining commercial profitability and preparing for multiple growth opportunities in 2026 [19] - The company is focused on strengthening its regional business and executing across its global pipeline [21] - Management expressed confidence in achieving corporate profitability, driven by top-line growth and disciplined investment [45] Other Important Information - The company has advanced Zoci from IND to global phase 3 in less than two years, reflecting the strength of its integrated U.S. and China development model [5] - The company is preparing for the commercial launch of KarXT in the second quarter of 2026, with a focus on building disease awareness and clinical confidence [19] Q&A Session Summary Question: Can you provide any color on how we should be thinking about revenues and expenses for 2026? - Management expects good growth opportunities for VYVGART and ZEJULA, with modest investments required to support launches [24][25] Question: Can you remind us of the implications of the intracranial activity in patients with brain mets for Zoci? - Zoci has shown an 80% response rate in patients with untreated brain metastases, which is a significant advantage [28] Question: Can you elaborate on the U.S., China development model? - The model allows for speedy development in China, which has led to successful registrations and efficient global trial participation [34][35] Question: What is the expectation for completion of enrollment and timing for Zoci's primary endpoint? - Enrollment is expected to finish by the end of Q1 2027, with a goal for accelerated approval in 2028 [50] Question: What is the strategy to grow VYVGART? - The focus is on increasing cycles per patient to a minimum of three, leveraging updated national guidelines [53][55]